CD34 and chronic kidney disease: However, the net change of creatinine level between baseline and the end of study period was relative lower in CKD-treatment group than in CKD-control counterpart [1.98–1.91/1.98 (3.5%) vs. 2.07–1.87/2.07 (9.7%), p = 0.667], implicating that CD34+ cell therapy may ameliorate the deterioration of renal function in CKD patients (Figure 2A).